Tagged with EY

Turkey Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95 percent of GDP last year, but the country plans to reach three percent of GDP by 2023. Multinational R&D investment…

Turkey Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in France, Greece, Italy, Spain or Portugal, converted to Turkish Lira at a rate of TRY 1.9595 per EUR,” says Cem…

Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…

manufacturing The managing director of Ejder Kimya, Pervin Ejder explains how the landscape for API and raw materials suppliers has evolved in Turkey, and how the company has pivoted into more value added and total packaged solutions to accommodate changing market dynamics. As an introduction for our readers, Pervin, can you…

Turkey Recep Altekin, the general manager of MT Sağlik – market leader in Turkey for blood glucose monitoring systems and diabetes test strips by volume – tells PharmaBoardroom about his company’s impact on the Turkish medical device industry, and the value-added solutions that come packaged under the MT umbrella. Can you break…

AstraZeneca   AstraZeneca’s Country President for Turkey discusses their efforts to build scientific leadership in Turkey in line with their global strategy and her hopes for the market access and public-private partnership environment in the coming years. The main value of AstraZeneca is putting the patient first and this is the…

Turkey PharmaBoardroom talked to Sr. Managing Director of Medtronic Turkey, Ayhan Ozturk about improving patient outcomes, how the company introduced a whole new standard on integrated healthcare, and their recent USD $25 million investment in a training facility.  Medtronic recently invested USD $25 million in a state-of-the-art training facility/Center of Innovation, which opened…

strategic levels Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also describes how the company’s new reagent facility in Germany will help bolster it domestically and regionally. Can you tell us…

Generics Earl Stanley Perez, General Manager of Meyerf Philippines, explains the importance of focusing on a few niches to succeed in a growing in a competitive market such as the Philippines, stressing the need for local companies to raise brand awareness and not only target the private sector but partner with…

Array   The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites the international life sciences com-munity to the island, the excitement was palpable. Foreign companies turned out in record numbers to…

Generics The CEO of Metiska Farma talks about coming back to Indonesia after studying in the US at Berkeley and MIT, to take over the company, and the company’s strategy of adding value through a portfolio of generics and OTC products. Can you begin by giving a brief introduction of Metiska…

Life Sciences James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech will be the leading industry in this new strategy and that less reliance on China will be necessary for an…